» Articles » PMID: 39524062

White Matter Lesion Volumes on 3-T MRI in People With MS Who Had Followed a Diet and Lifestyle Program for More Than 10 Years

Overview
Journal Mult Scler Int
Publisher Wiley
Date 2024 Nov 11
PMID 39524062
Authors
Affiliations
Soon will be listed here.
Abstract

: Cerebral white matter lesion (WML) formation in people with multiple sclerosis (pwMS) is linked to the death of myelin-producing oligodendrocytes. Current MS treatment strategies focus on limiting WML accumulation and disability. Using a pathology-supported genetic testing (PSGT) program, we identified specific risk factors for MS, categorized as and . We developed a novel clinical methodology to mitigate these risk factors, including personalized lifestyle interventions and optimization of cerebral nutrients to prevent oligodendrocyte demise and promote remyelination. : To conduct a pilot case-control study over a 10-year period to ascertain whether the PSGT Program can reduce or prevent WML formation in pwMS. : MRI was performed at baseline as well as after an interval period of at least 10 years or longer in 22 pwMS. WML volumes were determined using Sequence Adaptive Multimodal SEGmentation (SAMSEG) software, part of FreeSurfer 7.2. Other variables included age at MRI, disease duration, disability status, and medication. : PwMS ( = 13) who had followed the PSGT program for more than 10 years, had significantly smaller lesion volumes (mm) compared to pwMS who did not adhere to the program ( = 9) (4950 ± 5303 vs. 17934 ± 11139; = 0.002). WML volumes were significantly associated ( = 0.02) with disability (EDSS) but not with age ( = 0.350), disease duration ( = 0.709), or Interferon- treatment ( = 0.70). Dietary and lifestyle changes may lower the risk of developing cerebral WMLs in pwMS and potentially slow disease progression. Larger studies are required to confirm the effectiveness of such interventions in pwMS.

References
1.
Halabchi F, Alizadeh Z, Sahraian M, Abolhasani M . Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017; 17(1):185. PMC: 5602953. DOI: 10.1186/s12883-017-0960-9. View

2.
Cerri S, Puonti O, Meier D, Wuerfel J, Muhlau M, Siebner H . A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. Neuroimage. 2020; 225:117471. PMC: 7856304. DOI: 10.1016/j.neuroimage.2020.117471. View

3.
Munger K, Ascherio A . Understanding the joint effects of EBV and vitamin D in MS. Mult Scler. 2013; 19(12):1554-5. DOI: 10.1177/1352458513503723. View

4.
Kotze M, de Villiers J, Warnich L, Schmidt S, Carr J, Mansvelt E . Lack of clinical manifestation of hereditary haemochromatosis in South African patients with multiple sclerosis. Metab Brain Dis. 2006; 21(2-3):109-20. DOI: 10.1007/s11011-006-9015-4. View

5.
Wahls T, Titcomb T, Bisht B, Ten Eyck P, Rubenstein L, Carr L . Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial. Mult Scler J Exp Transl Clin. 2021; 7(3):20552173211035399. PMC: 8326636. DOI: 10.1177/20552173211035399. View